Accelerant, the insurtech empowering underwriters with superior risk exchange, data analytics, and capacity commitments, announced today that AM Best reaffirmed its Financial Strength Rating of A- and Long-Term Issuer Credit Rating of a-. This news was accompanied by Accelerant's increase to Financial Size IX, for companies with $250-500 million in adjusted policyholder surpluses.
In the recent update, Accelerant maintained both of its "Excellent" ratings. The increase in financial size indicates the size of the company in terms of statutory surplus and related accounts.
"The continued affirmation of our excellent ratings is a testament to our company's outstanding financial and organization strength," said Jeff Radke, CEO and co-founder of Accelerant. "The increase to Financial Size IX is also a significant milestone for our business and our Member partners, as our differentiated approach to driving best-in-class outcomes continues to resonate across the industry."
Accelerant specializes in serving a carefully selected and managed network of specialist underwriters and program administrators. To that end, Accelerant's data platform helps that network better understand risk, benefit from insights, and handle operational and regulatory complexity. Together, Accelerant works with its underwriting-led Members to drive market-leading profitable growth, focusing on the small and medium-sized businesses that power our global economy and their niche insurance needs.
ABOUT ACCELERANT
Accelerant is a data-driven, technology-fueled insurtech that empowers underwriters with superior risk exchange, advanced data analytics, and long-term capacity commitments. Our full-service risk exchange supports our carefully selected, best-in-class network of underwriting teams. We leverage granular information on each policy to deliver unprecedented insight into insurance pools, and our specialty portfolio is fully diversified with very low catastrophe, aggregation, or systemic risk. We're proud to have been awarded an AM Best A- (Excellent) rating. For more information, please visit www.accelins.com.
These press releases may also interest you
|